Vivus
| Vivus | |
|---|---|
| legal form | Incorporated |
| founding | 1991 |
| Seat | Campbell , CA USA |
| management | Seth HZ Fischer, CEO |
| sales | $ 124.3 million (2016) |
| Branch | pharmacy |
| Website | www.vivus.com |
Vivus (spelling "VIVUS") is an American pharmaceutical company that has been listed on the American technology exchange NASDAQ since 1991 under the label VVUS and is headquartered in Campbell , California . The company primarily develops drugs that are used to improve quality of life (i.e. weight loss or erectile dysfunction ). The Statutory Health Insurance Modernization Act excludes - in Germany - a reimbursement from the health insurance companies.
Products
Vivus has the following products on the market:
- Avanafil (trade name in EU: Spedra ; in USA: Stendra )
- Combination preparation of phentermine and topiramate (approval in the EU rejected; trade name in USA: Qsymia )
Approval of the above-mentioned combination preparation for the EU (intended trade name: Qsiva) was rejected in October 2012 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) . A retrial initiated by Vivus ended in February 2013 with another rejection.
In September 2017, the European Medicines Agency (EMA) granted the company orphan drug status for tacrolimus for the treatment of pulmonary hypertension (PAH) .
On July 7, 2020, Vivus Inc. filed for Chapter 11 bankruptcy .
See also
Statutory health insurance modernization law PDE-5 inhibitors
Web links
Individual evidence
- ↑ a b c FAQs ( Memento of the original from May 12, 2017 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , Company WebSite, accessed May 15, 2017
- ↑ Management Team ( Memento of the original from May 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Company WebSite, accessed May 15, 2017
- ↑ VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results ( Memento of the original from May 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM VIVUS of March 8, 2017, accessed on May 15, 2017
- ↑ Qsiva - Key facts , EMA website, last updated on February 22, 2013, accessed on May 16, 2017
- ↑ VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension ( Memento of the original dated November 7, 2017 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM VIVUS dated September 6, 2017, accessed on November 1, 2017
- ^ BRIEF-Vivus files for Chapter 11 bankruptcy in Delaware - court filing. In: reuters.com. July 7, 2020, accessed on July 8, 2020 .
